X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · IEX Real-Time Price · USD
1.390
-0.020 (-1.42%)
At close: Mar 28, 2024, 4:00 PM
1.370
-0.020 (-1.44%)
After-hours: Mar 28, 2024, 7:25 PM EDT
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 3.20, with a low estimate of 1.00 and a high estimate of 5.00. The average target predicts an increase of 130.22% from the current stock price of 1.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for XFOR stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 3 | 3 | 3 | 3 | 3 | 1 |
Hold | 0 | 0 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 7 | 7 | 7 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +115.83% | Mar 22, 2024 |
B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $3 → $1 | Strong Buy → Hold | Downgrades | $3 → $1 | -28.06% | Dec 12, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +115.83% | Aug 11, 2023 |
Stifel | Stifel | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +259.71% | May 17, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +115.83% | May 5, 2023 |
Financial Forecast
Revenue This Year
32.09M
Revenue Next Year
64.94M
from 32.09M
Increased by 102.39%
EPS This Year
-0.46
from -0.57
EPS Next Year
-0.35
from -0.46
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 123.8M | 171.3M | 308.3M | 488.0M | 318.8M |
Avg | 32.1M | 64.9M | 103.2M | 177.1M | 180.4M |
Low | 1.4M | 4.2M | 13.6M | 48.7M | 112.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | 433.7% | 374.7% | 372.7% | 80.1% |
Avg | - | 102.4% | 59.0% | 71.5% | 1.9% |
Low | - | -87.0% | -79.0% | -52.8% | -36.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.06 | -0.07 | 0.23 | 0.64 | 0.42 |
Avg | -0.46 | -0.35 | -0.21 | 0.06 | 0.08 |
Low | -0.68 | -0.56 | -0.50 | -0.28 | -0.11 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 648.7% |
Avg | - | - | - | - | 40.9% |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.